Literature DB >> 16750885

Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine.

Filipe Dantas-Torres1.   

Abstract

Canine visceral leishmaniosis is a life-threatening disease caused by Leishmania infantum. For quite some time, specialists in leishmaniosis have tried to develop more affordable and effective control measures against this disease. In this search, the first vaccine against canine visceral leishmaniosis was recently licensed in Brazil. In the light of recent research, the Leishmune vaccine might be seen as the newest tool for prevention and control of canine visceral leishmaniosis. Moreover, the potential of the Leishmune as a transmission-blocking vaccine has recently been demonstrated, indicating its usefulness in the control of zoonotic visceral leishmaniosis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16750885     DOI： 10.1016/j.vetpar.2006.05.001

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN： 0304-4017            Impact factor:   2.738


  16 in total

Review 1.  Current status of veterinary vaccines.

Authors:  Els N T Meeusen; John Walker; Andrew Peters; Paul-Pierre Pastoret; Gregers Jungersen
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

2.  Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

Authors:  Joelma Trigo; Melissa Abbehusen; Eduardo M Netto; Maria Nakatani; Geraldo Pedral-Sampaio; Robson Silva de Jesus; Yasuyuki Goto; Jeffrey Guderian; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

3.  Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs.

Authors:  Yasuyuki Goto; Randall F Howard; Ajay Bhatia; Joelma Trigo; Maria Nakatani; Eduardo M Netto; Steven G Reed
Journal:  Vet Parasitol       Date:  2008-11-05       Impact factor: 2.738

Review 4.  Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model.

Authors:  Ana Nieto; Gustavo Domínguez-Bernal; José A Orden; Ricardo De La Fuente; Nadia Madrid-Elena; Javier Carrión
Journal:  Vet Res       Date:  2011-02-23       Impact factor: 3.683

5.  Manifestations of paediatric Leishmania infantum infections in Malta.

Authors:  David Pace; Thomas N Williams; Alicja Grochowska; Alexandra Betts; Simon Attard-Montalto; Michael J Boffa; Cecil Vella
Journal:  Travel Med Infect Dis       Date:  2011-01-05       Impact factor: 6.211

6.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

7.  Canine vector-borne diseases in Brazil.

Authors:  Filipe Dantas-Torres
Journal:  Parasit Vectors       Date:  2008-08-08       Impact factor: 3.876

8.  Development of Leishmania vaccines: predicting the future from past and present experience.

Authors:  Joshua Muli Mutiso; John Chege Macharia; Maria Ndunge Kiio; James Maina Ichagichu; Hitler Rikoi; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-09-30

9.  Canine leishmaniosis in South America.

Authors:  Filipe Dantas-Torres
Journal:  Parasit Vectors       Date:  2009-03-26       Impact factor: 3.876

10.  A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.

Authors:  Connor Carson; Maria Antoniou; Maria Begoña Ruiz-Argüello; Antonio Alcami; Vasiliki Christodoulou; Ippokratis Messaritakis; Jenefer M Blackwell; Orin Courtenay
Journal:  Vaccine       Date:  2008-12-16       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.